Immunotherapy Regimen MKC-1106-MT

An immunotherapy regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase. After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a "primed" cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells. (NCI Thesaurus)

YOU MAY ALSO LIKE

Immunotherapy

A type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection,…

Immunotherapeutic GSK1572932A

An immunotherapeutic containing a proprietary adjuvant system combined with a melanoma-associated antigen peptide MAGE-A3 epitope with potential immunomodulating and antineoplastic activities. Intramuscular…

Immunosuppressive therapy

Therapy used to decrease the body's immune responses, such as drugs given to prevent transplant rejection.

Immunosuppressive Effect

An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components…

Immunosuppressive agent

An agent that decreases the body’s immune responses. It reduces the body’s ability to fight infections and other diseases, such as…

Immunosuppressive

Describes the ability to decrease the body's immune system responses.